Cargando…

EGFR mediates hyperlipidemia-induced renal injury via regulating inflammation and oxidative stress: the detrimental role and mechanism of EGFR activation

Previous studies have implicated inflammation, oxidative stress, and fibrosis as key factors in the development of obesity-induced kidney diseases. Epidermal growth factor receptor (EGFR) plays an important role in cancer development. Recently, the EGFR pathway has been increasingly implicated in ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Qilu, Zou, Chunpeng, Zhong, Peng, Lin, Feng, Li, Weixin, Wang, Lintao, Zhang, Yali, Zheng, Chao, Wang, Yi, Li, Xiaokun, Liang, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029707/ https://www.ncbi.nlm.nih.gov/pubmed/27014908 http://dx.doi.org/10.18632/oncotarget.8222

Ejemplares similares

EGFR Inhibition Blocks Palmitic Acid-induced inflammation in cardiomyocytes and Prevents Hyperlipidemia-induced Cardiac Injury in Mice
por: Li, Weixin, et al.
Publicado: (2016)

Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to TLR4 accessory protein MD2
por: Wang, Yi, et al.
Publicado: (2017)

Author Correction: Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to TLR4 accessory protein MD2
por: Wang, Yi, et al.
Publicado: (2018)

Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II
por: Peng, Kesong, et al.
Publicado: (2016)

11β-HSD1 inhibition ameliorates diabetes-induced cardiomyocyte hypertrophy and cardiac fibrosis through modulation of EGFR activity
por: Zou, Chunpeng, et al.
Publicado: (2017)

EGFR inhibition attenuates diabetic nephropathy through decreasing ROS and endoplasmic reticulum stress
por: Xu, Zheng, et al.
Publicado: (2017)

Blockade of myeloid differentiation protein 2 prevents obesity‐induced inflammation and nephropathy
por: Fang, Qilu, et al.
Publicado: (2017)

Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress
por: Wang, Lintao, et al.
Publicado: (2017)

EGFR signaling in renal fibrosis
por: Zhuang, Shougang, et al.
Publicado: (2014)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
por: Li, Ling, et al.
Publicado: (2020)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma
por: Pu, Yeong-Shiau, et al.
Publicado: (2009)

Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2)
por: Xu, Zheng, et al.
Publicado: (2017)

Author Correction: Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2)
por: Xu, Zheng, et al.
Publicado: (2021)

EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR
por: Wang, Anbang, et al.
Publicado: (2020)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Inhibition of inflammation and oxidative stress by an imidazopyridine derivative X22 prevents heart injury from obesity
por: Qian, Yuanyuan, et al.
Publicado: (2016)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
por: Liu, Yan, et al.
Publicado: (2019)

Is Testosterone Detrimental to Renal Function?
por: Filler, Guido, et al.
Publicado: (2016)

Downregulation of NEDD4L by EGFR signaling promotes the development of lung adenocarcinoma
por: Li, Guoyin, et al.
Publicado: (2022)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun
por: Li, Ying, et al.
Publicado: (2016)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Detrimental impact of hyperlipidemia on the peripheral nervous system: A novel target of medical epidemiological and fundamental research study☆
por: Wu, Song, et al.
Publicado: (2012)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

Air pollution, EGFR mutation, and cancer initiation
por: Han, Si-Chong, et al.
Publicado: (2023)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Attenuation of Hyperlipidemia- and Diabetes-Induced Early-Stage Apoptosis and Late-Stage Renal Dysfunction via Administration of Fibroblast Growth Factor-21 Is Associated with Suppression of Renal Inflammation
por: Zhang, Chi, et al.
Publicado: (2013)

Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance
por: Han, Ruoshuang, et al.
Publicado: (2021)

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
por: Zhu, Yan-juan, et al.
Publicado: (2017)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
por: Wang, Zhi, et al.
Publicado: (2022)

Vascular Inflammation and Hyperlipidemia: The Neutrophil Within
por: Rodriguez-Garcia, Marta, et al.
Publicado: (2021)

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
por: Zhang, Shi-Ling, et al.
Publicado: (2023)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4vm8r3qm8t0aacn5p2k4sgvt2k